NRx Pharmaceuticals, Inc. (NRXP) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga Sep. 14, 2021, 07:50 AM ...

NRX Pharmaceuticals shares are moving higher on Tuesday after it invested $27 million in its subsidiary HOPE Therapeutics.

Order Reprints Gift this Article NRx Pharmaceuticals CEO Steve Willard NRx By John George – Senior Reporter, Philadelphia Business Journal Jun 5, 2023 Preview this article 1 min ...

NRx said it expected to commence a Phase IIb/III registration trial of BriLife immediately after review by the study’s Data Safety Monitoring Board of the Phase II results during the week of ...

NRx has already won EUA for the COVID-19 drug in the nation of Georgia. 10 stocks we like better than NRx Pharmaceuticals, Inc. When our award-winning analyst team has a stock tip, it can pay to ...

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

NRX shares are trading higher on Thursday after the company announced a joint acquisition initiative with Hope Therapeutics to buy Kadima Neuropsychiatry Institute.